{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-019752","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.688329+00:00","generated_at":"2026-06-14T09:24:09.056179+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem reports Q1 preliminary: Phexxi sales up 35% to $5.8M, operating loss down 85%","bullets":["Net product sales of Phexxi rose >35% to ~$5.8M in Q1 2023 from $4.3M in Q1 2022.","Total operating expenses cut >70% to ~$9.4M vs $33.2M in prior-year quarter.","Loss from operations decreased >85% to ~$3.6M from $28.9M a year ago.","Company on track for quarterly EBITDA breakeven by year-end 2023.","Regained compliance with debt covenants via May 18 reverse stock split."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-019752","json":"https://secwatch.observer/filing/0001493152-23-019752.json","markdown":"https://secwatch.observer/filing/0001493152-23-019752.md","text":"https://secwatch.observer/filing/0001493152-23-019752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223019752/0001493152-23-019752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223019752/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T09:24:09.056179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b83ad800934968b2060cefe35516483e0f6e3fd0","claim":"Evofem Biosciences, Inc. reported the first quarter of 2023 results: revenue approximately $5.8 million. Guidance reaffirmed.","evidence_excerpt":"hormone-free prescription contraceptive gel, Phexxi ® (lactic acid, citric acid and potassium bitartrate) . ● Increased Phexxi net product sales more than 35% to approximately $5.8 million in Q1 2023, versus $4.3 million in Q1 2022. ● Reduced total operating expenses more than 70% to approximately $9.4 million, versus $33.2 million in Q1 2022. ● Decreased loss","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315223019752/0001493152-23-019752-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"approximately $5.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}